MYL(SH:600993) Xin Lang Cai Jing·2025-10-10 02:30Core Viewpoint - Ma Yinglong's stock price has shown a positive trend with an 8.12% increase year-to-date, reflecting a stable performance in the pharmaceutical sector [1][2]. Financial Performance - For the first half of 2025, Ma Yinglong achieved a revenue of 1.949 billion yuan, representing a year-on-year growth of 1.11% [2]. - The net profit attributable to shareholders for the same period was 343 million yuan, marking a year-on-year increase of 10.04% [2]. Stock Market Activity - As of October 10, Ma Yinglong's stock price was 27.56 yuan per share, with a market capitalization of 11.88 billion yuan [1]. - The stock experienced a trading volume of 81.90 million yuan and a turnover rate of 0.70% [1]. - Over the past five trading days, the stock price increased by 4.79%, while it rose by 3.34% over the last 20 days [1]. Shareholder Information - As of June 30, the number of shareholders decreased by 23.07% to 31,100 [2]. - The average number of circulating shares per shareholder increased by 29.98% to 13,825 shares [2]. Dividend Distribution - Since its A-share listing, Ma Yinglong has distributed a total of 1.633 billion yuan in dividends, with 591 million yuan distributed over the past three years [3]. Institutional Holdings - As of June 30, Hong Kong Central Clearing Limited was the third-largest circulating shareholder, holding 12.3912 million shares, an increase of 132,400 shares from the previous period [3]. - New institutional shareholders include Fortune Tianhui Growth Mixed Fund and Huatai-PineBridge Healthcare Mixed Fund, indicating growing interest from institutional investors [3].